Efficacy of 0.5% hyperbaric bupivacaine with nalbuphine hydrochloride and 0.5% hyperbaric bupivacaine with dexmedetomidine in neuraxial blockade for lower abdominal and orthopedic surgeries

Dr. E. Hari Bhagavan; Dr. A. Sriram

Volume : VIII, Issue : IV, April - 2018

Efficacy of 0.5% hyperbaric bupivacaine with nalbuphine hydrochloride and 0.5% hyperbaric bupivacaine with dexmedetomidine in neuraxial blockade for lower abdominal and orthopedic surgeries

Dr. E. Hari Bhagavan, Dr. A. Sriram

Abstract :

BACKGROUND: A clinical study was undertaken in 60 patients belonging to ASA 1 & 2 scheduled for lower abdominal and orthopedic surgeries with intrathecal Nalbuphine hydrochloride 0.8mg and Dexmedetomidine 10μg as an adjuvant to 0.5% hyperbaric bupivacaine 15mg to compare sensory and motor block in view of onset, level, degree, duration and adverse effects.

METHODOLOGY: They are allocated randomly into two groups: GROUP D and GROUP N, 30 members each to compare the effectiveness of intrathecal Nalbuphine hydrochloride 0.8mg and Dexmedetomidine 10μg as an adjuvant to 0.5% hyperbaric bupivacaine 15mg.

In Group D, 30 patients received Inj. Bupivacaine (15mg) + Inj.Dexmedetomidine (10μg )

intrathecally.

In Group N, 30 patients received Inj. Bupivacaine (15mg) + Inj. Nalbuphine (0.8mg) intrathecally.

RESULT: In group D , onset, duration and level of sensory and motor blockade, duration of analgesia were superior compared to group N. Hemodynamics were preserved both intraoperatively and postoperatively in group D.

CONCLUSION: Dexmedetomidine 10mcg with 0.5% hyperbaric bupivacaine 15mg when given intrathecally hastened sensory and motor onset, prolonged the sensory and motor block and improved the quality of analgesia with preserved hemodynamics.